Modeling Whole-Body Dynamic PET Microdosing Data to Predict the Whole-Body Pharmacokinetics of Glyburide in Humans [0.03%]
基于全身动态微剂量PET数据的格列本脲人体药代动力学预测模型构建
Léa Comin,Solène Marie,Moreno Ursino et al.
Léa Comin et al.
Introduction: Whole-body dynamic (WB4D) positron emission tomography (PET) imaging data using radiolabeled analogs of drugs are mostly analyzed using descriptive approaches, with no relationship to traditional pharmacokin...
Population Pharmacokinetic Modeling of Canagliflozin in Advanced Chronic Kidney Disease [0.03%]
坎格列净在晚期慢性肾病患者中的群体药代动力学研究
Elias John Elenjickal,Thomas A Mavrakanas,Ari Gritsas et al.
Elias John Elenjickal et al.
Background and objectives: Canagliflozin is an orally active, selective, reversible sodium-glucose cotransport-2 (SGLT-2) inhibitor used in patients with chronic kidney disease (CKD) to prevent cardiovascular (CV) events ...
Paracetamol Concentrations and Time-Course of Ductus Arteriosus Diameter in Extremely Preterm Neonates: A Population Pharmacokinetic-Pharmacodynamic Analysis [0.03%]
极早产新生儿的对乙酰氨基酚浓度和动脉导管直径的时间过程：人群药代动力学-药效学分析
Faheemah Padavia,Jean-Marc Treluyer,Gilles Cambonie et al.
Faheemah Padavia et al.
Background: Patent ductus arteriosus is a common complication of extreme prematurity. Prophylactic treatment with indomethacin or ibuprofen has shown efficacy on ductus closure but without reducing mortality and morbidity...
Hybrid Population Pharmacokinetic-Machine Learning Modeling to Predict Infliximab Pharmacokinetics in Pediatric and Young Adult Patients with Crohn's Disease [0.03%]
用于预测克罗恩病儿科及年轻人群英夫利西单抗药代动力学的混合人群药代动力学-机器学习模型
Kei Irie,Phillip Minar,Jack Reifenberg et al.
Kei Irie et al.
Background and objective: Population pharmacokinetic (PK) model-based Bayesian estimation is widely used for dose individualization, particularly when sample availability is limited. However, its predictive accuracy can b...
Evaluation of Preliminary Bronchodilation Effect on Aerosol Delivery from a Dry Powder Inhaler for Patients with Chronic Obstructive Pulmonary Disease with Suboptimal Peak Inspiratory Flow Rate [0.03%]
峰值吸气流速不佳的慢性阻塞性肺病患者使用干粉吸入剂的初步支气管扩张效果评价
Mohamed Ismail Hassan,Nabila Ibrahim Laz,Yasmin M Madney et al.
Mohamed Ismail Hassan et al.
Background: Suboptimal peak inspiratory flow rates (PIFR) are common in patients with chronic obstructive pulmonary disease (COPD), hindering effective medication dispersion and aerosol delivery. This study aimed to asses...
Correction: Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of Aficamten [0.03%]
Correction: 肝功能或肾功能损害对aficamten药代动力学影响的研究
Donghong Xu,Justin D Lutz,Punag Divanji et al.
Donghong Xu et al.
Published Erratum
Clinical pharmacokinetics. 2025 Aug 23. DOI:10.1007/s40262-025-01557-6 2025
Challenging Traditional ADME Assumptions for Physiologically Based Pharmacokinetic Models for Intravenous Administration of Iron-Carbohydrate Nanomedicines: Potential Utility of Gold Nanoparticle Models as a Roadmap [0.03%]
用于静脉给药的铁-碳水化合物纳米药物的基于生理的药代动力学模型对传统ADME假设的挑战：金纳米颗粒模型作为路线图的潜在效用
Amy Barton Alston,Zhoumeng Lin,Heather Herd Gustafson et al.
Amy Barton Alston et al.
Intravenous iron-carbohydrate complexes are a class of nanomedicines that are widely used globally to treat iron deficiency and iron deficiency anemia associated with a wide spectrum of disease states. Despite being widely used in clinical ...
Immunoglobulin G Receptors (FcγR), in Addition to Target-Antigen and Neonatal Fc Receptor (FcRn), Influence Rituximab Pharmacokinetics [0.03%]
除了靶抗原和新生儿Fc受体（FcRn），免疫球蛋白G受体（FcγR）也影响利妥昔单抗的药代动力学性质
David Ternant,Olivier Le Tilly,Guillaume Cartron et al.
David Ternant et al.
Introduction: Rituximab, an anti-cluster of differentiation (CD)-20 monoclonal antibody, is used in the treatment of non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia, and rheumatoid arthritis. The pharmacokinetics...
Methodological Techniques Used in Machine Learning to Support Individualized Drug Dosing Regimens Based on Pharmacokinetic Data: A Scoping Review [0.03%]
基于药代动力学数据支持个性化药物剂量方案的机器学习方法研究：范围回顾
Janthima Methaneethorn,Khanita Duangchaemkarn,Brad Reisfeld et al.
Janthima Methaneethorn et al.
Background and objective: Individualized drug dosing is a highly effective strategy for optimizing therapeutic outcomes, especially for drugs with high inter-individual variability. Population pharmacokinetic modeling is ...
Clinical Pharmacology Profile of the Claudin 18.2 Antibody Zolbetuximab [0.03%]
靶向Claudin 18.2抗体zolbetuximab的临床药理学特征分析
Jianning Yang,Akihiro Yamada,Kohei Shitara et al.
Jianning Yang et al.
Zolbetuximab is a first-in-class chimeric (mouse/human) monoclonal antibody targeted to the tight junction protein claudin 18.2 (CLDN18.2), an emerging biomarker in gastric/gastroesophageal junction (G/GEJ) cancer. This review summarizes th...